Physician

Christopher John Scully, M.D.

According to 2025 Medicare claims, Christopher Scully, M.D. (NPI: 1760437842) practices rheumatology in the Reno, NV market, with the plurality of this provider's patient population coming from Washoe, NV. This provider's primary affiliated billing organization is BACHMAN AND SCULLY, LTD. (NPI: 1841245792; TIN: 880426331) and primary practice location at 89511-4040. Scully is affiliated with the Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Scully's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 342 traditional Medicare patients, billed 124,630 HCPCS/CPT codes, and received $1,044,375 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,129 prescription claims across 354 beneficiaries totaling $3,969,031 in drug costs, led by Enbrel Sureclick (Etanercept). 2016 DME data shows 12 claims. Open Payments data shows 12 records totaling $161. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,229,480 to $3,969,031. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	476	78,669	$734,831
2016	437	78,049	$946,993
2017	422	58,357	$1,134,536
2018	399	64,832	$1,086,480
2019	402	87,491	$1,200,034
2020	355	92,200	$1,300,377
2021	331	109,808	$1,306,652
2022	381	106,520	$1,189,234
2023	359	113,593	$1,116,361
2024	342	124,630	$1,044,375

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	409	4,161	$1,229,480
2016	413	4,274	$1,928,350
2017	381	4,137	$2,525,552
2018	366	3,681	$2,662,459
2019	366	3,412	$2,998,058
2020	346	3,181	$3,014,637
2021	336	2,999	$4,070,485
2022	366	2,891	$4,128,314
2023	350	2,983	$4,786,974
2024	354	3,129	$3,969,031

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	12	$2,181
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	200	244	$80
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	161	198	$58
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	172	220	$11
96372	Injection of drug or substance under skin or into muscle	67	442	$11
J7050	Infusion, normal saline solution, 250 cc	58	375	$1

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Enbrel Sureclick	Etanercept	104	3,166	$808,533
Xeljanz Xr	Tofacitinib Citrate	84	2,520	$501,586
Humira(Cf) Pen	Adalimumab	33	1,204	$358,652
Xeljanz	Tofacitinib Citrate	42	1,680	$312,188
Rinvoq	Upadacitinib	43	1,607	$298,013

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	12	$161	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Christopher John Scully, M.D.?

Tedicare shows public-source Medicare data for Christopher John Scully, M.D. (NPI 1760437842), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Christopher John Scully, M.D. have ACO affiliation data?

Christopher John Scully, M.D. is shown with ACO affiliation data for Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Christopher John Scully, M.D.?

Christopher John Scully, M.D. is linked to BACHMAN AND SCULLY, LTD. (billing NPI 1841245792) in the available physician profile data.

Does Christopher John Scully, M.D. have Open Payments data?

Christopher John Scully, M.D. has 12 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.